Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017

EXECUTIVE SUMMARY

SECTION 1: CLINICAL BACKGROUND

• 1.1 Cardiovascular Disorders Applicable for Stent Implantation
  • 1.1.1 Acute Closure
  • 1.1.2 Restenosis After Angioplasty
• 1.2 Risk Factors for Coronary Heart Disease
• 1.3 Stenting vs. CABG and Angioplasty
• 1.4 Alternative Therapies for Coronary Atherosclerosis
  • 1.4.1 Angioplasty With or Without Stenting
  • 1.4.2 Atherectomy
  • 1.4.3 Coronary Artery Bypass Graft (CABG)
    • 1.4.3.1 Open CABG
    • 1.4.3.2 Off-Pump Coronary Artery Bypass (OPCAB)
    • 1.4.3.3 MIDCAB (Minimally Invasive Direct Coronary Bypass)
    • 1.4.3.4 RACAB (Robotic Assisted Coronary Artery Bypass)
    • 1.4.3.5 Other Forms of CABG
  • 1.4.4 Transmyocardial Laser Revascularization (TMR)
  • 1.4.5 Genetic Therapies
  • 1.4.6 HDL Therapy
  • 1.4.7 Drug-Eluting Balloons
  • 1.4.8 Nanoparticles and Other Agents
• 1.5 Incidence and Prevalence of Cardiovascular Stenting Procedures
• 1.6 Complications Related to Cardiovascular Stents

SECTION 2: PRODUCTS, TECHNOLOGIES

• 2.1 Materials Used in Cardiovascular Stents
• 2.2 Various Stent Shapes and Resulting Impact
• 2.3 FDA Approval of Cardiovascular Stents
• 2.4 Reimbursement of Drug-Eluting Stents
• 2.5 Bare Metal Stents
• 2.6 Drug-Eluting Stents
  • 2.6.1 Abbott Vascular
  • 2.6.2 Boston Scientific
  • 2.6.3 Johnson & Johnson/Cordis
  • 2.6.4 Medtronic
  • 2.6.5 Other Drug-Eluting Stent Companies
• 2.7 Bioabsorbable Stents
• 2.8 Other Types of Stents
• 2.9 Legal Proceedings
• 2.10 Key Clinical Trials
  • 2.10.1 HORIZONS AMI
  • 2.10.2 SYNTAX
  • 2.10.3 SPIRIT
  • 2.10.4 COURAGE
  • 2.10.5 PROTECT
  • 2.10.6 ENDEAVOR
  • 2.10.7 FAME
  • 2.10.8 SORT OUT III
  • 2.10.9 DAPT
  • 2.10.10 ZEST

SECTION 3: MARKETS FORECASTS AND COMPETITOR SHARES

• 3.1 Worldwide Market for Coronary Stents
  • 3.1.1 Worldwide Market for Drug-Eluting Coronary Stents
  • 3.1.2 Worldwide Market for Bare Metal Coronary Stents
  • 3.1.3 Worldwide Market for Absorbable Coronary Stents
• 3.2 U.S. Market for Coronary Stents
  • 3.2.1 U.S. Market for Drug-Eluting Coronary Stents
  • 3.2.2 U.S. Market for Bare Metal Coronary Stents
  • 3.2.3 U.S. Market for Absorbable Coronary Stents
• 3.3 European Market for Coronary Stents
  • 3.3.1 European Market for Drug-Eluting Coronary Stents
  • 3.3.2 European Market for Bare Metal Coronary Stents
  • 3.3.3 European Market for Absorbable Coronary Stents
• 3.4 Asia/Pacific Market for Coronary Stents
  • 3.4.1 Asia/Pacific Market for Drug-Eluting Coronary Stents
  • 3.4.2 Asia/Pacific Market for Bare Metal Coronary Stents
  • 3.4.3 Asia/Pacific Market for Absorbable Coronary Stents
• 3.5 Rest of World (ROW) Market for Coronary Stents
  • 3.5.1 ROW Market for Drug-Eluting Coronary Stents
  • 3.5.2 ROW Market for Bare Metal Coronary Stents
  • 3.5.3 ROW Market for Absorbable Coronary Stents

SECTION 4: COMPANY PROFILES

• 4.1 Aachen Resonance GmbH
• 4.2 Abbott Vascular
• 4.3 AdvanSource Biomaterials Corporation
• 4.4 Aeon Bioscience
• 4.5 Allvivo Vascular, Inc.
• 4.6 Amaranth Medical, Inc.
• 4.7 amg International GmbH
• 4.8 Arterial Remodeling Technologies (ART)
• 4.9 Atrium Medical
• 4.10 Avantec Vascular
• 4.11 B. Braun Melsungen
• 4.12 Balton Ltd.
• 4.13 Bioabsorbable Therapeutics, Inc.
• 4.14 Bioring SA
• 4.15 Biosensors International
• 4.16 Biotronik
• 4.17 Blue Medical Devices B.V.
• 4.18 Boston Scientific
• 4.19 Caliber Therapeutics
• 4.20 Cappella Inc.
• 4.21 CardioMind, Inc.
• 4.22 CeloNova BioSciences, Inc.
• 4.23 CID S.r.l. (Formerly Sorin Vascular Therapy)
• 4.24 Cinvention AG (Formerly Blue Membranes)
• 4.25 CorNova
• 4.26 CV Therapeutics/Gilead Inc.
• 4.27 Devax
• 4.28 DISA Vascular
• 4.29 Elixir Medical Corp.
• 4.30 Estracure Inc.
• 4.31 eucatech AG
• 4.32 Genesis Technologies, LLC
• 4.33 Global Therapeutics (Cook Medical)
• 4.34 Hexacath
• 4.35 ICON Interventional (Formerly ICON Medical Corp.)
• 4.36 InspireMD
• 4.37 InTek Technology
• 4.38 Invatec s.r.l.
• 4.39 ITGI Medical Ltd.
• 4.40 Johnson & Johnson
  • 4.40.1 Cordis
  • 4.40.2 Conor Medsystems (J&J)
• 4.41 JW Medical Systems / Biosensors International
• 4.42 Kaneka Corporation
• 4.43 Kyoto Medical Planning Co., Ltd.
• 4.44 Lepu Medical
• 4.45 Lutonix, Inc.
• 4.46 Medinol/ARIAD Pharmaceuticals
• 4.47 Medlogics Device Corporation (MDC)
• 4.48 Medtronic Vascular
• 4.49 Miami Cardiovascular Innovations
• 4.50 Micell Technologies
• 4.51 MicroPort Scientific Corporation
• 4.52 Minvasys
• 4.53 MIV Therapeutics
• 4.54 mNEMOSCIENCE GmbH
• 4.55 MoBeta, Inc.
• 4.56 NanoInterventions, LLC
• 4.57 Neovasc, Inc.
• 4.58 Nexeon MedSystems, Inc.
• 4.59 Opto Circuits (India) Ltd.
  • 4.59.1 EuroCor GmbH
• 4.60 OrbusNeich
• 4.61 Palmaz Scientific, Inc.
• 4.62 Picarus NV
• 4.63 Possis Medical (Bayer)
• 4.64 Prescient Medical
• 4.65 Relisys Medical Devices
• 4.66 REVA Medical
• 4.67 Sahajanand Medical Technologies
• 4.68 Stentys SAS
• 4.69 Terumo
• 4.70 Translumina
• 4.71 TriReme Medical
• 4.72 Tryton Medical
• 4.73 Vascular Concepts
• 4.74 VasoTech, Inc.
• 4.75 X-Cell Medical
• 4.76 Xtent, Inc. (ceasing operations)

APPENDIX I: SELECTED CLINICAL TRIALS

• ABSORB
• ARRIVE II Registry
• ARTS
• AXXESS PLUS
• BASKET
• BBC ONE
• CARE
• COREL
• COSTAR
• COURAGE
• CUSTOM
• DEScover Registry
• DIRECT
• DIVERGE
• e-HEALING
• EASTER Registry
• ENDEAVOR
• ETHOS
• EuroSTAR
• EVENT Registry
• FAME
• GENESIS
• FOCUS
• HEALING
• HORIZONS-AMI
• ISAR, ISAR-TEST-2
• LONG DES
• NOBLESS
• NOBORI
• NORDIC
• OLYMPIA Registry
• PASSION
• PREPARE
• PROGRESS
• RESOLUTE
• RESORB
• REWARD Registries
• SERIES
• SIMPLE Registries
• SIRIUS, E-SIRIUS, C-SIRIUS
• SORT-OUT III
• SPIRIT
• STEALTH
• STEMI
• STENT Registry
• SVELT
• TAXUS
• TYPHOON
• ZEST-AMI
• ZOMAXX

APPENDIX II: COMPANY DIRECTORY

• Exhibit ES-1: Types of Cardiovascular Disease and Incidence in the United States, 2006
• Exhibit ES-2: Prevalence, Mortality and Hospital Discharges for Cardiovascular Disease Patients in the United States
• Exhibit ES-3: Potential Complications Related to Implantation of Cardiovascular Stents
• Exhibit ES-4: Types of Coronary Stents and Selected Anti-Restenosis Devices
• Exhibit ES-5: Worldwide DES Market by Company, Calendar 4th Quarter, 2008
• Exhibit ES-6: Worldwide Market for Coronary Stents, by Type, Revenue Forecast, 2008 - 2017
• Exhibit ES-7: Worldwide Market for Drug-Eluting Coronary Stents, by Region, Revenue Forecast, 2008 - 2017
• Exhibit ES-8: Worldwide Market for Bare Metal Coronary Stents, by Region, Revenue Forecast, 2008 - 2017
• Exhibit ES-9: Worldwide Market for Absorbable Coronary Stents, by Region, Revenue, 2012 - 2017
• Exhibit 1-1: Types of Cardiovascular Disease and Incidence in the United States, 2006
• Exhibit 1-2: International Death Rates Per 100,000 Population for Total Cardiovascular Disease and Coronary Heart Disease for the Top 20 Countries
• Exhibit 1-3: Prevalence, Mortality and Hospital Discharges for Cardiovascular Disease Patients in the United States
• Exhibit 1-4: Drug-Eluting Balloon Catheters
• Exhibit 1-5: Estimated Inpatient Cardiovascular Procedures, U.S., 2006 (000)
• Exhibit 1-6: Number of Discharges, Coronary Atherosclerosis, U.S.
• Exhibit 1-7: National Healthcare Cost and Utilization Project Statistics: Mean Charges and In-Hospital Death Rates for Various Cardiovascular Procedures, U.S.
• Exhibit 1-8: Total Number of Cardiac Revascularization Discharges and Mean Charges, U.S., 1993 - 2006
• Exhibit 1-9: Total Number of Discharges for PCI Procedures with Non-Drug-Eluting Stents and Mean Charges, U.S., 2002 - 2006
• Exhibit 1-10: Total Number of Discharges for PCI Procedures with Drug-Eluting Stents and Mean Charges, U.S., 2002 - 2006
• Exhibit 1-11: Total Number of Discharges for PCI Procedures with Non-Drug and Drug-Eluting Stent Discharges and Mean Charges, U.S., 2002 - 2006

• Exhibit 2-1: Competitors in the Market for Bare Metal Stents
• Exhibit 2-2: Competitors in the Market for Drug-Eluting Stents
• Exhibit 2-3: Competitors in the Market for Bioresorbable Stents
• Exhibit 2-4: Competitors in the Market for Novel Stent Technologies

• Exhibit 3-1: Worldwide Coronary Stent Market, Unit and Revenue Forecast, 2008-2017
• Exhibit 3-2: Worldwide Drug-Eluting Coronary Stent Market, Unit and Revenue Forecast, 2008-2017
• Exhibit 3-3: Revenues for Leading Drug-Eluting Stent Market Competitors, Worldwide, 2008
• Exhibit 3-4: Worldwide Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
• Exhibit 3-5: Worldwide Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2012-2017
• Exhibit 3-6: U.S. Market for Coronary Stents, by Type, Revenue Forecast, 2008-2017
• Exhibit 3-7: U.S. Coronary Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017
• Exhibit 3-8: Revenues for Leading Drug-Eluting Stent Market Competitors, United States, 2008
• Exhibit 3-9: U.S. Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
• Exhibit 3-10: U.S. Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2013-2017
• Exhibit 3-11: European Coronary Stent Market, by Type, Revenue Forecast, 2008-2017
• Exhibit 3-12: European Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017
• Exhibit 3-13: European Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
• Exhibit 3-14: European Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2013-2017
• Exhibit 3-15: Asia/Pacific Market Forecasts for Coronary Stents, by Type, Revenue Forecast, 2008-2017
• Exhibit 3-16: Asia/Pacific Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017
• Exhibit 3-17: Asia/Pacific Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
• Exhibit 3-18: Asia/Pacific Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2012-2017
• Exhibit 3-19: Rest of World Coronary Stent Market, by Type, Revenue Forecast 2008-2017
• Exhibit 3-20: Rest of World Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017
• Exhibit 3-21: Rest of World Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
• Exhibit 3-22: Rest of World Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2012-2017

• Exhibit 4-1: AdvanSource Biomaterials Third Quarter Financial Results ($000s)
• Exhibit 4-2: Medtronic Financial Data, Third Quarter 2009 ($millions)
• Exhibit 4-3: Medtronic' s Coronary Stent Revenues, FY 2008 & 2009 ($millions)
• Exhibit 4-4: Xtent Financial Data, Fourth-Quarter 2008 ($millions)